Diabetic Retinopathy

Overview

Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus and the leading cause of vision loss among working-age adults¹. Chronic hyperglycemia damages retinal capillaries, and the resulting ischemia and vascular leakage drive a spectrum of disease from mild background changes to sight-threatening neovascularization¹.

Epidemiology & Risk Factors

DR is the most common microvascular complication of diabetes, and its likelihood rises with duration of disease and degree of glycemic control¹. Strict glycemic control and early screening are the two interventions most consistently tied to slowing progression¹.

Pathophysiology

The retina has an unusually high oxygen demand and a high concentration of polyunsaturated fatty acids, which makes it particularly vulnerable to the oxidative stress caused by sustained hyperglycemia⁵. In nonproliferative disease, damaged capillaries form microaneurysms that leak fluid and blood into the retina; when that leakage reaches the macula, it produces macular edema¹. As ischemia worsens, the retina releases angiogenic signals that drive the neovascularization defining proliferative disease¹.

Clinical Presentation

Early disease is frequently asymptomatic, which is why routine screening — not symptom-triggered visits — is the standard of care¹. As disease progresses, patients may report blurred or fluctuating vision, most often from macular edema, floaters from vitreous hemorrhage, or sudden vision loss from advanced complications¹.

Exam Findings

On dilated fundus exam, nonproliferative disease shows microaneurysms, dot-blot hemorrhages, and hard exudates, with venous dilation or beading as severity increases¹. Proliferative disease is defined by neovascularization of the disc or elsewhere in the retina, which carries a high risk of vitreous hemorrhage and tractional retinal detachment if untreated¹.

Classification

The modified Airlie House / ETDRS classification remains the reference standard for staging severity from stereoscopic fundus photographs, separating disease into nonproliferative grades and proliferative disease². For macular edema specifically, ETDRS criteria define clinically significant macular edema (CSME) using thresholds for retinal thickening and hard exudates within defined distances of the macular center³.

Differential Diagnosis

• Hypertensive retinopathy
• Retinal vein occlusion
• Radiation retinopathy
• Ocular ischemic syndrome
• Other causes of macular edema (Irvine-Gass syndrome, uveitis, retinitis pigmentosa)³

Management

Historically, focal and scatter laser photocoagulation guided by ETDRS treatment criteria has been a mainstay for both macular edema and proliferative disease, improving outcomes in a meaningful subset of patients³. Randomized trial data from the Diabetic Retinopathy Clinical Research Network established that intravitreal anti-VEGF therapy (ranibizumab) combined with prompt or deferred laser outperforms laser plus triamcinolone for diabetic macular edema, and anti-VEGF agents are now central to first-line management⁴.

Complications

Untreated proliferative disease can progress to vitreous hemorrhage, tractional retinal detachment, and neovascular glaucoma, any of which can cause severe, often irreversible vision loss¹.

Clinical Pearls

• Screening intervals should be driven by disease stage, not symptoms — many sight-threatening changes are silent until late.
• Macular edema and proliferative disease are staged independently; a patient can have severe macular edema with only mild background retinopathy.
• Anti-VEGF therapy has shifted first-line management of diabetic macular edema away from laser-only protocols⁴.

Common Pitfalls

• Relying on visual acuity alone to gauge severity — acuity can be preserved despite advanced peripheral retinopathy.
• Forgetting that pregnancy can accelerate progression, warranting closer surveillance.
• Treating "diabetic retinopathy" as a single entity rather than grading NPDR/PDR and macular edema status separately, which changes management.